ENTBF (Entheon Biomedical) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2026)


What is Entheon Biomedical LT-Debt-to-Total-Asset?

Entheon Biomedical ENTBF LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Entheon Biomedical's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.00.

Entheon Biomedical's long-term debt to total assets ratio stayed the same from Feb. 2025 (0.00) to Feb. 2026 (0.00).

Entheon Biomedical  (OTCPK:ENTBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Entheon Biomedical LT-Debt-to-Total-Asset Related Terms

Entheon Biomedical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Entheon Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical LT-Debt-to-Total-Asset Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23 Nov24 Nov25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entheon Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entheon Biomedical LT-Debt-to-Total-Asset Calculation

Entheon Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2025 is calculated as

LT Debt to Total Assets (A: Nov. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Nov. 2025 )/Total Assets (A: Nov. 2025 )
=0/0.252
=

Entheon Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )/Total Assets (Q: Feb. 2026 )
=0/0.208
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Entheon Biomedical (ENTBF) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Entheon Biomedical and its competitors.
Is Entheon Biomedical's LT-Debt-to-Total-Asset too high?
Entheon Biomedical's current LT-Debt-to-Total-Asset is 0.00.
How does Entheon Biomedical's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Entheon Biomedical's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Entheon Biomedical and its competitors. Entheon Biomedical's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entheon Biomedical Business Description

Other Exchanges 1XU:GermanyENBI.X:Canada
Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company focused on treating addiction and substance use disorders.